UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B.
German pharma and chemicals group Bayer may finally have put long-running litigation over its weedkiller Roundup in its rear view mirror – but at an eye-watering cost of more t
Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat